Page last updated: 2024-09-22

(4-tert-Butyl-phenoxy)-acetic acid

Cross-References

ID SourceID
PubMed CID15718
CHEMBL ID435539
CHEBI ID186680
SCHEMBL ID1283871

Synonyms (49)

Synonym
nsc 8481
BB 0217641
1798-04-5
p-tert-butylphenoxyacetic acid
4-(1,1-dimethylethyl)phenoxyacetic acid
nsc-8481
mls000737895 ,
acetic acid,1-dimethylethyl)phenoxy]-
nsc8481
(4-tert-butylphenoxy)acetic acid
OPREA1_117986
(p-tert-butylphenoxy)acetic acid
2-(4-tert-butylphenoxy)acetic acid
smr000071302
MLS000099546
OPREA1_073109
(4-tert-butyl-phenoxy)-acetic acid
AK-968/40879410
STK317911
AKOS000103796
CHEMBL435539
CHEBI:186680
2-[4-(tert-butyl)phenoxy]acetic acid
2-(4-(tert-butyl)phenoxy)acetic acid
A812486
HMS2382G17
4-tert-butylphenoxyacetic acid ,
FT-0633849
(4-tert-butyl-phenoxy)acetic acid
p-t-butylphenoxyacetic acid
para-t-butylphenoxyacetic acid
FBIGAJNVRFKBJL-UHFFFAOYSA-N
4-tert-butylphenoxy acetic acid
4-t-butylphenoxyacetic acid
SCHEMBL1283871
cambridge id 6771050
DTXSID50170863
acetic acid, 2-[4-(1,1-dimethylethyl)phenoxy]-
acetic acid, [4-(1,1-dimethylethyl)phenoxy]-
mfcd00021758
4-tert-butylphenoxyacetic acid, >=98.0% (hplc)
SR-01000242822-1
sr-01000242822
E10123
CS-0196874
AS-10381
EN300-00118
?4-tert-butylphenoxyacetic acid
Z56867222

Drug Classes (1)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency10.00000.044717.8581100.0000AID485294
LuciferasePhotinus pyralis (common eastern firefly)Potency21.33130.007215.758889.3584AID588342
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency8.91250.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.41250.035520.977089.1251AID504332
survival motor neuron protein isoform dHomo sapiens (human)Potency25.11890.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Receptor-type tyrosine-protein phosphatase betaHomo sapiens (human)Kis450.00003.73005.66507.6000AID775020
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
protein dephosphorylationReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
phosphate-containing compound metabolic processReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
glial cell migrationReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
dephosphorylationReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
angiogenesisReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
transmembrane receptor protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
protein bindingReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
cadherin bindingReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
specific granule membraneReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
tertiary granule membraneReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
receptor complexReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID22013Solubility ratio ([HbS+drug (20 mM)]/[HbS-drug]1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID775020Competitive inhibition of human GST-tagged LMW-PTP-B expressed in Escherichia coli JM 109 cells using p-nitrophenyl phosphate as substrate after 15 mins by microplate reader analysis2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Identification of new inhibitors for low molecular weight protein tyrosine phosphatase isoform B.
AID21143Solubility of Deoxyhemoglobin S (dHbS) concentration after addition dithionite as control1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID22012Solubility ratio ([HbS+drug (10 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID1130306Inhibition of glycolic acid oxidase (unknown origin) assessed as enzyme-mediated reduction of NaDCIP by sodium glycolate after 1 to 3 mins by spectrophotometer analysis1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Quantitative structure-activity relationships involving the inhibition of glycolic acid oxidase by derivatives of glycolic and glyoxylic acids.
AID21145Solubility of Haemoglobin S (HbS) concentration after addition of acid and dithionite1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID22149Solubility ratio ([HbS+drug (5 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (18.18)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's6 (54.55)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]